Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season

Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season

Background Respiratory syncytial virus (RSV) is an important cause of severe respiratory illness in older adults and adults with certain health conditions. Adjuvanted RSVPreF3 and non-adjuvanted RSVpreF vaccines were approved in 2023 for use in adults aged ≥60 years in the United States (US). This s...

Full description

Saved in:
Bibliographic Details
Main Authors: Frederik Verelst, David Singer, Jonathan Graham, Mei Grace, Elizabeth M. La, Eliana Biundo
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Expert Review of Vaccines
Subjects:
Public health impact
respiratory syncytial virus
vaccination
United States
Markov model
Online Access:https://www.tandfonline.com/doi/10.1080/14760584.2025.2539893
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items